Background. The fluid filling renal cysts in human polycystic kidneys is secreted chiefly by the tubular epithelium lining the cysts via secondary chloride transport. Inhibiting this process by somatostatin therapy should induce shrinking of renal cysts. Methods. In this randomized, cross-over, placebo-controlled trial we compared the risk/benefit profile of 6-month treatment with long-acting somatostatin (octreotide-LAR, 40 mg intramuscularly every 28 days) or placebo in autosomal-dominant polycystic kidney disease (ADPKD) patients with mild-to-moderate renal insufficiency and no evidence of other kidney disease. Volumes of kidney structures were evaluated by a two-slice computed tomography (CT) scanner; while glomerular filtration rate (GFR) was estimated by iohexol plasma clearance. Results. One patient on somatostatin and one on placebo were prematurely withdrawn because of nonsymptomatic, reversible colelithiasis and asthenia, respectively. In the remaining 12 patients somatostatin was well tolerated. Kidney volume increased by 71 ± 107 mL (P < 0.05) on somatostatin and by 162 ± 114 mL (P < 0.01) on placebo. The percent increase was significantly lower on somatostatin (2.2 ± 3.7% vs. 5.9 ± 5.4%) (P < 0.05). Cystic volume tended to increase less on somatostatin than on placebo (3.0 ± 6.5% vs. 5.6 ± 5.8%). The "parenchymal" volume nonsignificantly increased by 2.5 ± 8.4% on placebo and slightly decreased by 4.4 ± 8.9% on somatostatin. The GFR did not change significantly during both treatment periods. Conclusion. In ADPKD patients, 6-month somatostatin therapy is safe and may slow renal volume expansion. This may reflect an inhibited growth in particular of smallest cysts beyond the detection threshold of CT scan evaluation. Whether this effect may prove renoprotective in the long term should be tested in additional trials of longer duration.

(2005). Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease [journal article - articolo]. In KIDNEY INTERNATIONAL. Retrieved from http://hdl.handle.net/10446/204284

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

Remuzzi, Andrea;
2005-01-01

Abstract

Background. The fluid filling renal cysts in human polycystic kidneys is secreted chiefly by the tubular epithelium lining the cysts via secondary chloride transport. Inhibiting this process by somatostatin therapy should induce shrinking of renal cysts. Methods. In this randomized, cross-over, placebo-controlled trial we compared the risk/benefit profile of 6-month treatment with long-acting somatostatin (octreotide-LAR, 40 mg intramuscularly every 28 days) or placebo in autosomal-dominant polycystic kidney disease (ADPKD) patients with mild-to-moderate renal insufficiency and no evidence of other kidney disease. Volumes of kidney structures were evaluated by a two-slice computed tomography (CT) scanner; while glomerular filtration rate (GFR) was estimated by iohexol plasma clearance. Results. One patient on somatostatin and one on placebo were prematurely withdrawn because of nonsymptomatic, reversible colelithiasis and asthenia, respectively. In the remaining 12 patients somatostatin was well tolerated. Kidney volume increased by 71 ± 107 mL (P < 0.05) on somatostatin and by 162 ± 114 mL (P < 0.01) on placebo. The percent increase was significantly lower on somatostatin (2.2 ± 3.7% vs. 5.9 ± 5.4%) (P < 0.05). Cystic volume tended to increase less on somatostatin than on placebo (3.0 ± 6.5% vs. 5.6 ± 5.8%). The "parenchymal" volume nonsignificantly increased by 2.5 ± 8.4% on placebo and slightly decreased by 4.4 ± 8.9% on somatostatin. The GFR did not change significantly during both treatment periods. Conclusion. In ADPKD patients, 6-month somatostatin therapy is safe and may slow renal volume expansion. This may reflect an inhibited growth in particular of smallest cysts beyond the detection threshold of CT scan evaluation. Whether this effect may prove renoprotective in the long term should be tested in additional trials of longer duration.
articolo
2005
Ruggenenti, Piero; Remuzzi, Andrea; Ondei, Patrizia; Fasolini, Giorgio; Antiga, Luca; Ene-Iordache, Bogdan; Remuzzi, Giuseppe; Epstein, Franklin H....espandi
(2005). Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease [journal article - articolo]. In KIDNEY INTERNATIONAL. Retrieved from http://hdl.handle.net/10446/204284
File allegato/i alla scheda:
File Dimensione del file Formato  
1-s2.0-S0085253815508284-main.pdf

accesso aperto

Versione: publisher's version - versione editoriale
Licenza: Creative commons
Dimensione del file 286.25 kB
Formato Adobe PDF
286.25 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Aisberg ©2008 Servizi bibliotecari, Università degli studi di Bergamo | Terms of use/Condizioni di utilizzo

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10446/204284
Citazioni
  • Scopus 224
  • ???jsp.display-item.citation.isi??? 191
social impact